Lower extremity peripheral artery disease (PAD) significantly affects aging populations and results in functional impairment. Although the clinical importance of finding efficacious interventions for PAD is well-recognized, few medical therapies are currently available. PAD is diagnosed using the ankle brachial index (ABI), a measure of blood flow to the lower extremities. Lower ABI is associated with worse function; however, low ABI alone cannot fully explain functional impairments in PAD. Small studies have reported oxidative stress, mitochondrial dysfunction and/or fiber damage in gastrocnemius muscle biopsies from PAD patients, suggesting skeletal muscle perturbations may contribute to functional decline. We reported highly variable fiber type composition and fiber type grouping in a small cohort of PAD patients, and observed lack of intermyofibrillar mitochondria (IMFM-) in oxidative, myosin heavy chain (MyHC) type I fibers. We have provocative new preliminary data suggesting variability in response to ongoing denervation, and in fiber type and mitochondrial adaptations, with PAD. The purpose of this study is to define specific characteristics of muscle in PAD associated with impaired walking performance through detailed immunohistochemical analyses of 400 baseline gastrocnemius muscle biopsies stored in the Northwestern biorepository, collected from 9 different clinical trials. This biorepository of muscle from PAD patients is one-of-a-kind and is associated with detailed clinical and functional characteristics of the donors. We hypothesize that variability in fiber size, fiber type and mitochondrial adaptations in response to ischemia-reperfusion damage and denervation in individuals with PAD will have value in predicting walking impairment.
In Aim 1, we will quantify the proportion of IMFM- areas in type I fibers with normal type I MyHC abundance, or accumulation of type IIX MyHC and/or LC3, a marker of autophagy, and determine associations with fiber type composition and fiber size, as well as relationships of muscle features to walking performance in PAD. We hypothesize that LC3 will co-localize with IIX MyHC in IMFM- areas, suggesting both incomplete autophagic clearance of IIX MyHC and mitochondrial biogenesis during fiber transition from type IIX to type I as a result of denervation and reinnervation.
In Aim 2 we will quantify denervated, NCAM+ fibers and fibers with elevated oxidative damage markers by fiber type. We hypothesize that denervation in PAD will preferentially affect fibers expressing IIX MyHC and that only IMFM- areas that accumulate IIX MyHC will be NCAM+.
In Aim 3 we will perform predictive modeling of PAD disease severity and functional impairment using morphological characteristics of muscle quantified in Aims 1 and 2 as biomarkers in conjunction with supervised classification approaches.
In Aim 4 we will test the hypothesis that baseline muscle characteristics will predict longitudinal functional outcomes at 6-month follow up. This model will provide a powerful tool to aide in identifying biologic processes for targeted interventions and to assess the mechanism of action and effectiveness of current pharmacological and exercise interventions in ongoing PAD clinical trials.
Peripheral artery disease (PAD) significantly affects aging populations and results in functional impairment and mobility loss. Few medical therapies are currently available to treat PAD because the underlying pathology in calf muscle is not understood. The goal of this study is identify aberrant properties of muscle to aide in the development of new targeted interventions to improve walking ability in individuals with PAD.
